Home » FDA Awards Priority Review to Gilead for Hep C Combo Drug
FDA Awards Priority Review to Gilead for Hep C Combo Drug
The FDA has granted priority review for Gilead Sciences’ once-daily, single-tablet combination of Sovaldi and NS5A inhibitor velpatasvir for hepatitis C.
Previously classified as a breakthrough therapy, the drugmaker’s case for the NDA stems from four international Phase 3 trials that tested more than 1,000 patients in all six HCV genotypes. Results from those trials showed sustained viral response in 98 percent of patients.
The FDA has set a PDUFA decision date of June 28. Gilead’s combination drug also is being evaluated in Europe.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May